All News

Article

Difficult-to-Manage AxSpA: Global Prevalence and Associated Factors

Nelly Ziade Jun 11, 2025

The concept of Difficult-to-Manage (D2M) axial spondyloarthritis (axSpA) is a recent development, with the first expert consensus definition published by the Assessment of SpondyloArthritis International Society (ASAS) earlier this year. This unified definition has stimulated a wave of new research globally, with multiple studies analysing D2M axSpA in diverse clinical cohorts.

#EULAR2025 Abstr#OP0077 Which MSK item/tool is important when assessing #SLE arthritis?Cohort study showed: -SJC = good specificity. Correlated with US synovitis but not patient-defined response -New tool, LAMDA correlated with US & patient response. May be used in RCT @RheumNow https://t.co/srVLKw2pcL

https://x.com/Yuz6Yusof/status/1932831273304613341/photo/1

❓️How effective and safe is it to combine bDMARDs and tsDMARDS (i.e. TNFi/ IL17i + JAKi/TYKi) in #psoriatic_arthritis? 🅰️ Reassuring data from a case-series study presented by Andre Lucas Ribeiro #EULAR2025 OP0090 @RheumNow #Strategy https://t.co/W8fuzSgxbJ

https://x.com/Nellziade/status/1932833759679963620/photo/1

Ph 2 RCT Sonelokimab (IL-17A- & IL-17F-inhibiting Nanobody) 24wks 207 pts SON 120 MDA 51% vs. 45% ADA Subgroups: female 52%, weight ≥100kg 53%, ≥3% BSA 55% Composite ACR70/PASI100 SON 120 48% vs. 19% ADA No new safety signal Ph 3 on the way 2 doses SON 60 &120 #OP0096 https://t.co/w5QtpKbi1W

Young Patients’ AREA empowers teens/young adults w/ autoimmune disease to shape research. US-based, youth-led & grounded in empowerment, they co-design studies, train peers & advise researchers. A truly positive and meaningful initiative esp for PPIE @RheumNow #EULAR2025 #OP0008

Efficacy and safety of deucravacitinib up to week 52 in the POETYK PsA-2 study •ACR20 at W16: 54.2% (deucravacitinib) vs 39.4% (placebo), p=0.0002 •PASI75: 40.9% vs 15.4%, p<0.0001 •MDA: 25.6% vs 14.7%, p=0.0007 •FACIT-F: +2.5 vs +1.8 •SAE: 1.9% (low) TYK2 inhibition shows https://t.co/JXTZRk2itA

https://x.com/synovialjoints/status/1932826757243019691/photo/1

❓️Is early intensive therapy with combination csDMARDs or TNFi superior to standard step care for the treatment of moderate to severe #psoriatic_arthritis? 🅰️ Yes 🔅Check out the SPEED RCT presented by @DrLauraCoates at #EULAR2025 OP0089 @RheumNow #Strategy https://t.co/24e7wUV2FB

https://x.com/Nellziade/status/1932827204171530655/photo/1

#EULAR2025 Abstr#OP0078 #Lupus nephritis is assoc with CVD. Propensity matched analysis comparing GLP-1 agonist vs SLGT2-i using TrinetX database in LN ->favourable risk reduction with GLP-1: -CKD progression -Mortality -MI Validation & mechanistic explanation needed @RheumNow https://t.co/xPDVDm1CHm

https://x.com/Yuz6Yusof/status/1932827720032928095/photo/1

In propensity-matched RA cohort (n=2,449 each) on JAK inhibitors, adding a GLP-1 agonist reduced risk of: • Acute coronary syndromes (RR 0.65, p=0.0009) • DVT (RR 0.69, p=0.007) Overall CV events ↓ by 33% (RR 0.67, p=0.0007) #EULAR2025 @RheumNow Abstract#OP0069 https://t.co/jWI6tvri8O

https://x.com/JihaRheum/status/1932820564793831909/photo/1

Can RA be intercepted? In the ALTO follow-up of the APIPPRA RCT (Cope et al), 1 year of abatacept delayed RA onset by up to 3 years in ACPA+/RF+ individuals. Effect strongest in those with mature autoantibody profiles. Abstract#OP0004 @RheumNow #EULAR2025 https://t.co/N7YwtYod8w

https://x.com/JihaRheum/status/1932820871367864579/photo/1

Repurposing drugs to #osteoarthritis No jewel in the rough! Most drugs - MTX, colchicine, TNFi, IL1i, etc are NEGATIVE or yield mixed results from diff #RCTs Not sure this is the way forward for #OA drug discovery 💡 #EULAR2025 @RheumNow @eular_org Abst#POS565 https://t.co/A6SdXtOo7v

https://x.com/Janetbirdope/status/1932821338445771088/photo/1

RA pts have ↑ risk of DVT (HR 2.26) & PE (HR 1.61) vs controls in this 40-year, pop-based study. Nodules, obesity, high disease activity & early biologic use ↑ risk. Remission in year 1 halved PE risk. VTE risk persists despite therapeutic advances. @RheumNow #EULAR2025 #OP0070 https://t.co/AaBi2o2cUw

https://x.com/DrMiniDey/status/1932821374638141601/photo/1

GI symptoms in axSpA -Cohort of 370 pts with axSpAfrom New Zealand -Elevated fecal calprotectin ➡️ positive correlation with GI symptoms and high disease activity -Bowel symptoms associated with reduced quality of life. -Use of TNFi improved bowel symptoms over time. https://t.co/wA37G3HWyi

IL-17 inhibition for PMR? In the secukinumab ph2 in GCA (TitAIN), patients with PMR did really well, seemingly outperforming steroid taper in the placebo arm. Real promise, will be great to see how the ph3 in PMR (REPLENISH) goes OP0062 #EULAR2025 @RheumNow https://t.co/cisA0GiUx1

https://x.com/drdavidliew/status/1932822621634109638/photo/1

MONITOR PsA 200+ pts secondary care "real-life" cohort 65 treated w/ combi csDMARDs 48weeks outcome and 96 weeks 49% bioDMARDs, 29% retention and 23% deescalation to 1 csDMARD ‼️reasons for discontinuation was AEs in 60% cases not inefficacy Caveat: analysis not adjusted for https://t.co/L8EczgZTpP

A PT-led vocational intervention for RA/axSpA with reduced work ability was likely cost-effective: ↓€4,324 in societal costs & +0.05 QALYs over 12m vs usual care (95% probability at €20k/QALY). Results suggest cost-effective compared to usual care. @RheumNow #EULAR2025 #OP0007

RA polygenic risk ≠ MI risk. In >8,700 Swedes w/ or w/o RA, higher genetic risk for RA wasn’t linked to higher MI incidence. Familial clustering of RA & MI likely driven by non-genetic factors. Traditional CV risk still key in RA care. @RheumNow #EULAR2025 #OP0072 https://t.co/KN6Dg0ekt2

https://x.com/DrMiniDey/status/1932824645662552347/photo/1

Xeligekimab in AS: -IL-17A blocker -Phase 3 study on Chinese pts showed sustained efficacy until week 48. -Significant improvement on DAI measures as well. -Fully humanized IgG4 mab may last longer in system and possible less ADAs. Abstract #OP0102 #EULAR2025 @RheumNow https://t.co/vyNHZ9ssFt

📊 POS0574 @rheumnow #EULAR2025 Real-world data from SERENA shows sustained 5-year effectiveness of secukinumab in PsA. ✔️ 57% had no tender/swollen joints at Year 5 ✔️ PASI90 in ~48% ✔️ Stable low TJC, SJC & PtGA Durability confirmed even in prior biologic users. https://t.co/eNpboTRRu3

https://x.com/JihaRheum/status/1932800240756650358/photo/1

Clinical determinants of multiple drug failure in D2T RA 2000+ RA cohort 250+ refractory -Low financial status -Cancer Hx -CV comorbidities -Chronic use of NSAID or GCs Protective: Regular participation in leisure activities #POS0030 @RheumNow #EULAR2025 https://t.co/qNHQoHCb80

Topics

All News

Difficult-to-Manage AxSpA: Global Prevalence and Associated Factors

Do you get our email newsletter?